| (−)-Meptazinol–melatonin hybrids as novel dual inhibitors of cholinesterases and amyloid-β aggregation with high antioxidant potency for Alzheimer’s therapy S Cheng, W Zheng, P Gong, Q Zhou, Q Xie, L Yu, P Zhang, L Chen, J Li, ... Bioorganic & Medicinal Chemistry 23 (13), 3110-3118, 2015 | 27 | 2015 |
| A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Cancer Research 82 (12_Supplement), 5313-5313, 2022 | 1 | 2022 |
| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 468 | 2019 |
| Abstract B009: A liver-tropic BCL-xL PROTAC effectively clears senescent hepatocytes and prevents NASH-driven HCC in mice Y Yang, N Jn-Simon, W Hu, P Zhang, G Zheng, L Pi, Y He, D Zhou Cancer Research 83 (2_Supplement_1), B009-B009, 2023 | 1 | 2023 |
| Abstract CC09-01: Targeting BCL-XL/BCL-2 by PROTAC 753b effectively eliminates AML cells and enhances efficacy of chemotherapy by targeting senescent cells Y Jia, Q Zhang, W Zhang, M Andreeff, N Jain, H Ma, P Zhang, G Zheng, ... Molecular Cancer Therapeutics 20 (12_Supplement), CC09-01-CC09-01, 2021 | | 2021 |
| Attenuating breast cancer metastasis with BCL-XL-targeting PROTACs ME Carelock, P Zhang, M Jiao, U De, Z Jin, RM Stump, SG Williams, ... Cancer Research 84 (6_Supplement), 4123-4123, 2024 | | 2024 |
| Bcl-2 proteins degraders for cancer treatment G Zheng, D Zhou, X Zhang, S Khan, HE Yonghan, P Zhang | 1 | 2019 |
| BCL-2 Proteins Degraders for Cancer Treatment G Zheng, D Zhou, X Zhang, S Khan, Y He, P Zhang US Patent App. 16/962,816, 2021 | | 2021 |
| BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Journal of Hematology & Oncology 15 (1), 23, 2022 | 34 | 2022 |
| Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells Y Jia, L Han, CL Ramage, Z Wang, CC Weng, L Yang, S Colla, H Ma, ... Haematologica 108 (10), 2626, 2023 | 19 | 2023 |
| Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice S Khan, P Kellish, N Connis, D Thummuri, J Wiegand, P Zhang, X Zhang, ... Cell Death Discovery 9 (1), 1, 2023 | 15 | 2023 |
| Compositions targeting senescent cells and the uses thereof D Zhou, G Zheng, X Zhang, Y Wang, J Chang, F Xia, MS De Almeida, ... US Patent App. 16/165,797, 2019 | 8 | 2019 |
| Concise Synthesis of (S)-δ-CEHC, a Metabolite of Vitamin E M Burke, P Pal, P Zhang, X Zhang, G Zheng ACS omega 6 (6), 4355-4361, 2021 | 1 | 2021 |
| DEGRADER OF BCL-2 PROTEIN FOR CANCER TREATMENT G Zheng, D Zhou, X Zhang, S Khan, HE Yonghan, P Zhang | | 2021 |
| Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production X Liu, Z Gao, Q Fu, L Song, P Zhang, X Zhang, H Hendrickson, PA Crooks, ... Bioorganic & medicinal chemistry 28 (11), 115498, 2020 | 8 | 2020 |
| Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL D Nayak, D Lv, Y Yuan, P Zhang, W Hu, A Nayak, EA Ruben, Z Lv, ... Nature communications 15 (1), 2743, 2024 | 2 | 2024 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 91 | 2021 |
| Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition P Pal, D Thummuri, D Lv, X Liu, P Zhang, W Hu, SK Poddar, N Hua, ... Journal of medicinal chemistry 64 (19), 14230-14246, 2021 | 34 | 2021 |
| Discovery of BCL-XL degraders as potent and platelet-sparing anticancer agents X Zhang, D Thummuri, S Khan, X Liu, P Zhang, D Zhou, G Zheng ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 258, 2019 | | 2019 |
| Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines X Zhang, Y He, P Zhang, V Budamagunta, D Lv, D Thummuri, Y Yang, ... European journal of medicinal chemistry 199, 112397, 2020 | 46 | 2020 |
Guangrong ZhengProfessor, University of Florida在 cop.ufl.edu 的电子邮件经过验证
